Résumé
Beta-lactams exhibit time-dependent bactericidal effects with continuous infusion (CI) suggested to provide superior antibiotic concentrations compared to intermittent bolus (IB).
To determine whether beta-lactam CI improves day 14 clinical cure compared to IB in a South African, multi-disciplinary intensive care unit (ICU).
Adult patients with sepsis receiving amoxicillin-clavulanate, piperacillin-tazobactam, imipenem-cilastatin and meropenem were randomized to 24-hour CI or IB. On screening, patients who received study antibiotics for more than 24 h, pregnant patients or patients on renal replacement therapy were excluded. The primary outcome, clinical cure, was defined as completion of antibiotics by day 14 without recommencement within 48 h. Secondary outcomes included ICU length of stay (LOS), ICU, day 28 and day 90 mortality.
We enrolled 122 patients. The groups were balanced for baseline age, weight, sex, severity of illness, organ support, HIV status, diagnostic category and site of infection. Median antibiotic duration, CI group, 7 days (IQR 5–8.5) vs. IB group, 6 days (IQR 4–8), p=0.191, and median ICU LOS, CI, 9.5 days (IQR 6–15.5) vs. IB, 9 days (IQR 5–16), p= 0.575, were similar. Clinical cure in the CI group was 81% (52/64) vs. 74.1% (43/58) in the IB group), p=0.345. Day 90 relative risk of death was 0,57, 95% Confidence Interval 0.32 – 1.01) for the CI group compared to IB.
Among critically ill patients meeting the sepsis-3 definition, this study could not demonstrate the superiority of continuous infusion of beta-lactam antibiotics compared to intermittent bolus in achieving a clinical cure.
•We compared continuous infusion versus intermittent bolus dosing of four beta-lactam antibiotics in a low middle income multi-disciplinary ICU.•This is the first clinical assessment of amoxicillin-clavulanate.•We demonstrated a trend towards improved clinical cure (7.2%) and mortality (Day 90 RR 0,57 (95% CI 0.32–1.01) for continuous infusion.•We explored continuous infusion beta-lactam administration in a setting with a high burden of sepsis caused by resistant microbes (60.2%).